Risk class definition for your medtech/digital health product.
Establish a quality management system.
Clinical risk management plan to support CE marking and/or FDA approvals.
Clinical evaluation to decide which clinical data to generate, how to design your trial(s), the optimal time to apply, and more.
Build your strategic roadmap for evidence demonstration and registration dossier filing.
Market access coaching, to identify the target population and select the best market & reimbursement price.
Understanding CE marking vs. FDA requirements – because Neighborhood and VCLS are built with one foot firmly planted on each side of the Atlantic, we can show you all the intricacies of both processes.
Digital Health
Digital Medical Device conception (62304 implementation)
Establishing software under the Medical Device status is a challenge. Different standards apply, and “agile” development is possible under certain conditions. Let Neighborhood show you how.
IVD (In Vitro Diagnostic)
Implementation IVDR 2017/746/EU
The development of an IVD follows a specific regulation which is constantly evolving. Neighborhood can help you meet these requirements.
Dedicated Team
Rym Boulkedid
Director, Clinical Operations Clinical
Neighbors
Orixha
AIINTENSE
AiiNTENSE optimizes the management of patients with acute or chronic neurological pathology, more particularly peri-resuscitation or associated with covid-19.
Based on the automated collection of clinically relevant elements of the patient record, AiiNTENSE platform is able to assist in the diagnosis and treatment of neurological pathology as well as its prognostic evaluation and follow-up, using a multimodal platform that integrates a health data portal, cognitive assistants, a monitoring application and a tele-expertise and teleconsultation network. It allows hospitals to guarantee full traceability of procedures, to reduce bed occupancy time and to save medical staff time.
The platform integrates outputs of specialized medical devices and algorithms developed in collaboration with medical R&D centers.
CERTIS THERAPEUTICS
CERTIS THERAPEUTICS has developed minimally invasive therapy solutions based on real-time MRI guidance. The company is a spinoff from IHU Liryc (Bordeaux, France), a leading international institute focused on better understanding and treating cardiac electric disorders. Our technology aims to improve both the efficacy and the safety of thermal ablation treatments.
CERTIS THERAPEUTICS’ core technology has been validated on various organs and addresses cardiology, oncology, and neurology.
Pharmacodynamic Modeling and Artificial Intelligence
Paris, France
HILLO
Hillo develops the first AI-based decision support platform for diabetic patients, based on a blood glucose levels predictive system that adapts to every patient’s physiology and habits.
Our technology combines pharmacodynamic modeling and artificial intelligence, we develop tools for patients to help them anticipate and avoid hypo- or hyperglycemia, and for care teams to help them understand each patient’s specific glycemic response. We’ve demonstrated outstanding results and accuracy of our predictive technology through trials in hospitals.
AIVISION
AgenT
AgenT is on a mission to detect Alzheimer’s when it can be prevented through a simple blood test. To prevent the onset of symptoms or stop the progression, we need to diagnose Alzheimer’s long before dementia.
By combining multi-omics biomarkers signals with machine learning, AgenT identifies Alzheimer’s patients that no other current diagnostic tool can detect.
They envision a future where routine health screenings include a blood test for Alzheimer’s to slow down the disease’s progression before it’s too late.
Hemerion
Each year, in Europe and in the US, more than 20,000 patients undergo surgery for a brain cancer. This condition remains incurable, but the quality of surgery significantly improves survival. The combination of a photosensitizer drug and a laser illumination device makes it possible to treat disseminated and inaccessible cancer cells during surgery. This technology offers new perspectives and developments on brain cancer therapy are already under clinical evaluation.
The proof of concept is established, the absence of toxicity is demonstrated and the first trials in humans show an improvement in patient survival. In this context, Hemerion aims to market this new modality for 2026.
Glaucome
Paris, France
BIOPHTA
Lack of adherence to Rx eye drops is the #1 Unmet Medical need in Ophthalmology. Poor treatment compliance leads to a worse progression of Eye Diseases. We will change lives of patients suffering from chronic eye diseases by creating a best-in-class solution reducing treatments burden.
Bubble removal for safer intravenous infusion
Ireland
Gasgon Medical
Intravenous therapy is the most common invasive therapy in healthcare, with 3.7 billion disposable IV tubes used each year, and complications from air bubbles are frequent and present serious risks of adverse events for patients. Gasgon Medical is developing ALOTIS, a closed-system aspirator device to safely remove bubbles from IV drugs including toxic chemotherapy drugs, thereby protecting patients and healthcare workers from occupational exposure, a key initiative of the European Health policy makers. Gasgon has plans to enter the market in Europe by 2022, with clinical study plans in place through its hospital partners.
Usense
Usense is a medtech company offering an innovative and miniaturized technology in medical biology. With one click, Usense allows users to measure precisely in urine the majority of health parameters which are typically analyzed in medical biology labs. By capitalizing on AI and machine learning, Usense detects the presence of markers fostering early diagnosis in medical consultation, emergency contexts, and pathology follow up.
MS Insight
MSInsight, a healthtech company, is empowering the fight against cancer by revealing actionable information from the genome.
MSICare is a next-generation sequencing-based in vitro diagnostic device for detection of microsatellite instability (MSI) using DNA isolated from formalin-fixed paraffin-embedded (FFPE) or frozen tumor tissue, matched with or without normal specimens from patients with solid or liquid malignant neoplasms.
Meet your new neighbors
We'd love to get to know you
Join us, we offer you an extraordinary chance to learn, develop and be part of an exciting experience, supported by a knowledgeable team.
Tell us your story